Gedea Biotech

Gedea Biotech, founded in 2016 as a spin-off from Lund University, is a Swedish company focused on women's health. The founders include Olov Sterner, a professor of chemistry, and Helena Strevens, a senior consultant in gynecology and obstetrics. Their combined expertise in chemistry and clinical practice led to the development of the company's lead product.

The company is developing pHyph, a vaginal tablet for the treatment and prevention of bacterial vaginosis (BV). This product is designed to be antibiotic-free, addressing the growing concern of antibiotic resistance. The treatment is based on a substance that restores the natural pH balance of the vagina, which helps to inhibit the growth of harmful bacteria while promoting the growth of beneficial bacteria. The business model centers on the development and subsequent commercialization of pHyph. The primary market is women's health, specifically targeting the large population of women affected by bacterial vaginosis. Revenue will likely be generated through sales of the product to healthcare providers and directly to consumers, pending regulatory approvals such as the CE marking for the European market.

The core product, pHyph, is a tablet that is inserted vaginally. Its main feature is its dual-action capability to both treat active infections and prevent recurrence. By avoiding antibiotics, it aims to offer a solution with fewer side effects and a lower risk of contributing to antimicrobial resistance. The company has conducted clinical trials to establish the safety and efficacy of pHyph.

Keywords: women's health, bacterial vaginosis, antibiotic-free, medical device, gynecology, vaginal health, clinical trials, biotech, life sciences, antimicrobial resistance